Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction on Monday, July 3rd. The stock was sold at an average price of $52.10, for a total value of $859,650.00. Following the sale, the chairman now owns 51,476 shares of the company’s stock, valued at approximately $2,681,899.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ionis Pharmaceuticals, Inc. (NASDAQ IONS) traded down 0.23% on Friday, hitting $51.60. 567,149 shares of the stock traded hands. The company’s 50 day moving average price is $48.73 and its 200-day moving average price is $46.13. The stock’s market cap is $6.40 billion. Ionis Pharmaceuticals, Inc. has a 52-week low of $24.34 and a 52-week high of $57.00.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Tuesday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.13. Ionis Pharmaceuticals had a negative net margin of 4.80% and a negative return on equity of 14.61%. The firm had revenue of $110.30 million for the quarter, compared to the consensus estimate of $86.03 million. During the same period in the prior year, the firm posted ($0.52) earnings per share. The firm’s quarterly revenue was up 199.2% compared to the same quarter last year. On average, analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.37) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Ionis Pharmaceuticals, Inc. (IONS) Chairman Stanley T. Crooke Sells 16,500 Shares” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/07/16/ionis-pharmaceuticals-inc-ions-chairman-sells-859650-00-in-stock-updated.html.

Several research analysts have recently weighed in on IONS shares. Leerink Swann reissued an “outperform” rating and set a $45.00 price target (down from $47.00) on shares of Ionis Pharmaceuticals in a research report on Wednesday, May 17th. TheStreet upgraded Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. BMO Capital Markets reiterated a “buy” rating and set a $59.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, June 2nd. Vetr raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating and set a $37.67 price target on the stock in a research report on Tuesday, March 21st. Finally, Piper Jaffray Companies set a $51.00 target price on Ionis Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 10th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $44.55.

Institutional investors have recently bought and sold shares of the stock. Hanseatic Management Services Inc. acquired a new stake in shares of Ionis Pharmaceuticals during the first quarter worth approximately $138,000. Westpac Banking Corp purchased a new stake in Ionis Pharmaceuticals during the first quarter valued at about $171,000. Capstone Asset Management Co. boosted its stake in Ionis Pharmaceuticals by 10.3% in the first quarter. Capstone Asset Management Co. now owns 5,148 shares of the company’s stock valued at $207,000 after buying an additional 480 shares during the last quarter. World Asset Management Inc raised its position in shares of Ionis Pharmaceuticals by 27.3% in the first quarter. World Asset Management Inc now owns 5,427 shares of the company’s stock valued at $218,000 after buying an additional 1,163 shares during the period. Finally, Raymond James Trust N.A. raised its position in shares of Ionis Pharmaceuticals by 2.9% in the first quarter. Raymond James Trust N.A. now owns 5,705 shares of the company’s stock valued at $229,000 after buying an additional 159 shares during the period. 88.73% of the stock is currently owned by institutional investors and hedge funds.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.